Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Metersky

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
The New England Journal of Medicine|June 23, 2006
Cyclophosphamide versus placebo in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
American Journal of Respiratory and Critical Care Medicine|August 25, 2007
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
Gastroenterology|March 16, 2025
Evolution of Esophageal Adenocarcinoma From Precursor Lesion Stem CellsWa Xian, Shan Wang, Jingzhong Xie, et al.
Annals of the American Thoracic Society|July 25, 2024
Postinfectious Pulmonary Complications: Establishing Research Priorities to Advance the Field: An Official American Thoracic Society Workshop ReportSara C Auld, Ajay Sheshadri, Jennifer Alexander-Brett, et al.
Chest|June 21, 2020
Treatment of Community-Acquired Pneumonia in Immunocompromised Adults: A Consensus Statement Regarding Initial StrategiesJulio A Ramirez, Daniel M Musher, Scott E Evans, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
The New England Journal of Medicine|June 23, 2006
Cyclophosphamide versus placebo in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
American Journal of Respiratory and Critical Care Medicine|August 25, 2007
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
Gastroenterology|March 16, 2025
Evolution of Esophageal Adenocarcinoma From Precursor Lesion Stem CellsWa Xian, Shan Wang, Jingzhong Xie, et al.
Annals of the American Thoracic Society|July 25, 2024
Postinfectious Pulmonary Complications: Establishing Research Priorities to Advance the Field: An Official American Thoracic Society Workshop ReportSara C Auld, Ajay Sheshadri, Jennifer Alexander-Brett, et al.
Chest|June 21, 2020
Treatment of Community-Acquired Pneumonia in Immunocompromised Adults: A Consensus Statement Regarding Initial StrategiesJulio A Ramirez, Daniel M Musher, Scott E Evans, et al.
Pageof 5